Norbert Avril

TL;DR: PET imaging may differentiate responding and nonresponding tumors early in the course of therapy by avoiding ineffective and potentially harmful treatment, this may markedly facilitate the use of preoperative therapy, especially in patients with potentially resectable tumors.

TL;DR: The number of invasive procedures is unlikely to be significantly reduced by PET imaging in patients presenting with abnormal mammography, however, the high positive-predictive value, resulting from the increased metabolic activity of malignant tissue, may be used with carefully selected subsets of patients as well as to determine the extent of disease or to assess therapy response.

TL;DR: The role of positron emission tomography using [18F]fluorodeoxyglucose (FDG) to monitor primary chemotherapy in patients with locally advanced breast cancer was addressed and significant differences in tracer uptake between nonresponding tumors and responding lesions were observed.

TL;DR: Histologic and immunohistochemical tissue analysis was unable to sufficiently explain the variation of FDG uptake in breast cancer, and FDG PET imaging may not be used to estimate tumor biologic behavior of breast cancer such as differentiation, histopathologic grading, cell proliferation, or axillary lymph node status.

TL;DR: The ability to image the location (distribution) of gene expression and the level of expression over time provides new and useful information for monitoring clinical gene therapy protocols in the future.